As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

As­traZeneca’s close­ly-watched PO­SEI­DON study con­tin­ues to be the rare bright spot in its push for an in-house PD-L1/CT­LA-4 com­bo.

Com­bin­ing Imfinzi and treme­li­mum­ab with physi­cians …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER